RAYONG, Thailand, March 8, 2024 /PRNewswire/ — SUPCON (688777.SH, SUPCON.SW), a trailblazer in process automation and digital transformation in China, announced the grand opening of its first 5S Store in Rayong, Thailand on March 6th 2024. This momentous occasion marks a significant move in SUPCON’s commitment to delivering top-notch local services to its customers in Thailand.
At the ceremony, the esteemed clients and partners including Indorama, TPE, TPC, TPIPL, Lenzing, Zhongce Rubber, COFCO, Quechen Silica extended heartfelt congratulations on this significant milestone. Mr. Guo Biao, Senior Vice President & Chief Marketing Officer of SUPCON, delivered a keynote address emphasizing the strategic importance of the Thai market to SUPCON and the pivotal role of the SUPCON 5S store in fostering local service innovation in Thailand.
5S Stores: A Comprehensive Service Hub
The 5S Stores concept stands as a comprehensive service hub, embodying “5S” which stands for Spare-parts, Specialists, Solutions, Sales, and Services. This approach aims to offer more accessible services, including same-day spare-parts delivery and immediate expert consultations. Complementing the 5S Stores is the S2B (Services to Business) online platform, which leverages AI technology to enhance spare-parts procurement efficiency and ensure precise inventory calculations.
Expanding Horizons: Rayong, Thailand, Southeast Asia
The inauguration of the Rayong 5S Store signifies SUPCON’s strategic expansion into Southeast Asia, underlining its commitment to delivering localized service excellence. With a global clientele of over 30,000 customers and a dedicated workforce of 6,000 employees, SUPCON has continuously prioritized the customer service experience. The proven success of the 5S store+S2B platform service model, with approximately 180 stores established in China, is poised for further expansion in industrial parks and clusters worldwide.
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
